News
Pediatric Praziquantel Consortium receives second Prix Galien Bridges Award nomination
The Pediatric Praziquantel Consortium, coordinated by Lygature, has once again been nominated for the prestigious Prix Galien Bridges Award in the Best Public Sector Innovation category. The nomination recognises the Consortium's achievement in developing a new treatment for schistosomiasis specifically designed for preschool-aged children.
This marks the second consecutive year that the international public-private partnership has received recognition in this category. For Lygature, which coordinated the Consortium throughout its journey, the nomination is a further acknowledgement of the value of long-term collaboration in addressing unmet global health needs.
Established in 2012 and concluded in 2026, the Pediatric Praziquantel Consortium brought together partners from academia, industry, public health, and the non-profit sector to address a longstanding treatment gap for children aged 3 months to 6 years affected by schistosomiasis.
The nomination, submitted by Lygature on behalf of the Consortium, reflects the collective achievements of the partners and the lasting impact of more than a decade of international collaboration.
The winners of the 2026 Prix Galien Bridges Awards will be announced at a ceremony on 1 December 2026 in Stockholm, Sweden.
For more information, read the Galien Foundation's official announcement.